Area of research
Oncology · Physiology
Research interest
Research focused on Oncology and Cohort, with related work in Docetaxel, Sorafenib, Biosimilar. Notable publications include 'SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial', 'First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial', and 'A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer'.
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.
A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer